Novel agents for cutaneous T-cell lymphoma.
Several novel therapies have recently emerged for the treatment of hematologic malignancies; several agents have demonstrated activity against T-cell lymphomas in vitro or in early clinical trials. This article discusses how these therapies may be implemented in the treatment of patients who have advanced or refractory cutaneous T-cell lymphoma.
Kuzel
Timothy M
TM
Division of Hematology/Oncology, The Feinberg School of Medicine, and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, 675 North St. Clair, Suite 21-100, Chicago, IL 60611, USA.
Junghans
Richard
R
Foss
Francine M
FM
D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D016503:Drug Delivery Systems; D015195:Drug Design; D006801:Humans; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy*; D051379:Mice; D016513:Mice, SCID; D012878:Skin Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents